

In May 2022, Marie brought her four children to be vaccinated against measles at one of the vaccination sites set up by MSF around Bangabola in the Democratic Republic of Congo.
The MSF team had been sent in to respond to yet another measles outbreak in DRC. During 2022, MSF carried out 45 measles-related emergency interventions to protect children from measles, which was more than three-quarters of our emergency response in DRC.
Measles is one of the most contagious and deadliest diseases to affect young children. It’s also – like many other childhood diseases – preventable through vaccination. Yet, families and caregivers, for a variety of reasons, sometimes can’t get easy access to the vaccine that could protect their children.
That's why MSF’s vaccination work is so vital, including by catching up children with vaccinations they may have missed out on. In Bangabola, our team vaccinated more than 33,000 children aged 6-59 months against measles. Beyond measles, the team also used the opportunity to vaccinate the children against other diseases.
MSF vaccination activities
MSF carries out vaccination activities in many places where we work to protect children. This includes reactive vaccination campaigns to help contain outbreaks of diseases such as measles, cholera, and yellow fever.
We also carry out preventive vaccination campaigns with routine vaccines to protect children against a range of diseases such as pneumonia, diarrhoea, tetanus.
MSF also intervenes to ensure children who live in remote areas, far from any routine health care, can benefit from the protection of vaccines.
However, there are still other barriers that stop many children getting vaccinated including: weak health systems and vaccination programs, difficulty accessing immunisation points especially by vulnerable groups, and government policies that don’t promote catching up children when they are identified, just to name a few.
MSF is working in several ways to overcome barriers to childhood immunisation to ensure many more children’s lives can be protected.
Campaign | 2022
If mRNA technology were shared, manufacturers in LMICs could produce vaccines for pandemic preparedness and diseases of concern.